MediWound
Update in progressMDWD (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
MediWound Ltd. is a biopharmaceutical company focused on tissue repair and regeneration. It develops, manufactures, and markets therapies for burn care and difficult-to-heal wounds, including NexoBrid, used in burn centers to remove eschar. It also develops EscharEx, a bromelain-based enzymatic treatment for chronic wounds, and MW005, a topical candidate for non-melanoma skin cancers. Headquartered in Yavne, Israel, it serves the U.S., Europe, and beyond.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.28
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationIsrael
- Founded2000
- Employees121
- Websitewww.mediwound.com
Identifiers
- ISINIL0011316309
- FIGIBBG005ZPKRQ4
- CUSIPM68830104
- CIK0001593984